We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Keywords: antiviral drug resistance; antiviral therapy; cytomegalovirus; maribavir; solid organ transplantation.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.